# Cartalax Peptide: What the Research Shows

**By TelosRX Editorial Team** · 2026-11-10

**Cartalax peptide is a lab-made tripeptide (Ala-Glu-Asp) studied as a cartilage bioregulator. Research so far is limited to cell cultures and reviews, with no human trials. [TelosRX](https://telosrx.com) breaks down what each study actually found.**

Cartalax peptide search interest has spiked lately. The marketing often runs well ahead of the science. So here's the evidence, study by study, with links you can check yourself.

One note up front. Cartalax is not FDA-approved for any use. Nothing below is a promise of results. It's a map of what researchers have and haven't measured.

## What Is Cartalax Peptide?

Cartalax is a synthetic version of a three-amino-acid chain: alanine, glutamic acid and aspartic acid. Researchers call it **AED** or Ala-Glu-Asp. Older papers also used the code T-31.

It belongs to a family called short regulatory peptides. These are tiny chains, two to four amino acids long. The theory is that they may influence which genes cells switch on.

## Where Cartalax Comes From

Nearly all Cartalax research comes from one research group in Saint Petersburg, Russia. That group, led for decades by gerontologist Vladimir Khavinson, has studied "peptide bioregulators" since the 1970s.

Their early work used peptide extracts from animal tissues. Cartilage extracts were found to contain short peptides, including AED. Cartalax is the lab-made form of that tripeptide.

That single-source origin matters. Independent replication is the gold standard in science. For Cartalax, it's largely missing.

## Cartalax Research at a Glance

| Study | Model | What was measured | Reported finding |
| --- | --- | --- | --- |
| Lin'kova et al., 2016 | Aging rat skin fibroblasts in culture | Ki-67, CD98hc, caspase-3, MMP-9 | AED lowered MMP-9 and caspase-3 markers; raised Ki-67 and CD98hc |
| Ashapkin et al., 2020 | Aging human mesenchymal stem cells in culture | IGF1, FOXO1, TERT, TNKS2, NF-κB gene expression | AED and related peptides raised IGF1 and NF-κB expression |
| Linkova et al., 2023 (review) | Literature review | Peptides and cartilage-forming stem cells | Notes AED is a component of cartilage peptide complexes; calls for more research |
| Human clinical trials | —   | —   | None published in indexed journals |

## Finding 1: AED Shifted Aging Markers in Rat Skin Cells

A 2016 study grew rat skin fibroblasts (collagen-making cells) until they aged in the dish. Researchers then added four short peptides, including AED ([Lin'kova et al., Bull Exp Biol Med, 2016](https://pubmed.ncbi.nlm.nih.gov/27259496/)).

-   All peptides reduced **MMP-9**, an enzyme that breaks down tissue scaffolding and rises with cell aging.
-   All peptides raised **Ki-67** (a proliferation marker) and **CD98hc** (a renewal marker).
-   AED and AEDG reduced **caspase-3**, a marker of programmed cell death.

What it means: in a dish, AED nudged several markers in a "younger" direction. What it doesn't mean: that the same happens in human skin or joints.

## Finding 2: AED Changed Gene Activity in Aging Stem Cells

A 2020 study used human bone-marrow mesenchymal stem cells. These cells can become cartilage, bone or fat. Researchers aged them two ways in culture, then added AED and two related peptides ([Ashapkin et al., Mol Biol Rep, 2020](https://pubmed.ncbi.nlm.nih.gov/32399807/)).

-   **IGF1** gene expression rose 3.5- to 5.6-fold with the peptides. IGF1 is a growth signal involved in tissue maintenance.
-   AED, KED and KE all stimulated **NF-κB** gene expression in both aging models.
-   The peptides worked at nanomolar concentrations, meaning very small amounts.

The authors conclude these peptides "modulate the expression of some genes known to be involved in cell aging." That's a careful claim. NF-κB is also a key inflammation switch. So more of it isn't automatically better.

## Finding 3: AED Is Part of Cartilage Peptide Complexes

A 2023 review examined how peptides might guide stem cells toward becoming cartilage ([Linkova et al., Int J Mol Sci, 2023](https://pmc.ncbi.nlm.nih.gov/articles/PMC10179481/)). It describes a cartilage-derived peptide complex containing short peptides, including AED.

The review summarizes the two cell studies above. It frames osteoarthritis research as an urgent unmet need. It does not report new human data on Cartalax.

## Why Cartalax Peptide Is Trending

Google searches for Cartalax jumped sharply this fall. Bioregulator peptides like Thymalin, Pinealon and Epitalon are getting attention at the same time. Social media and research-peptide sellers drive much of that interest. Search volume is not evidence, though. So let's keep going with what's been measured.

## How Cartalax Is Thought to Work

The proposed mechanism is gene regulation. The idea is that ultrashort peptides enter cells and interact with DNA or proteins that control gene activity. That could, in theory, shift cells toward repair rather than breakdown.

This is a hypothesis, not an established mechanism. It rests mostly on cell and computer-modeling studies from the same research network. Mainstream pharmacology hasn't confirmed it.

## Cartalax and Joint Health: Claims vs Evidence

Online sellers often describe Cartalax as a cartilage repair peptide. Here's how that lines up with the published record.

-   **Claim:** rebuilds cartilage. **Evidence:** no published human or animal cartilage-repair trial in indexed journals.
-   **Claim:** reduces joint inflammation. **Evidence:** cell data only, and NF-κB findings cut both ways.
-   **Claim:** slows joint aging. **Evidence:** marker shifts in aging cell cultures, not in joints.

## Cartalax and Skin Aging

The skin angle comes from the 2016 fibroblast study. Lower MMP-9 and higher renewal markers sound appealing for skin. But those results came from rat cells in a dish. No published study has tested Cartalax on human skin outcomes.

## What the Research Has Not Shown

-   No randomized controlled trials in people.
-   No published dose-finding or pharmacokinetic data (how the body absorbs and clears it).
-   No long-term safety data.
-   Little independent replication outside one research network.

That's not proof it doesn't work. It's proof nobody knows yet.

## Safety and Side Effects: What's Known

Very little. Short peptides break down into common amino acids, which is often cited as a reason they may be low-risk. But "probably low-risk" isn't the same as "studied and shown safe."

Products sold online as "research peptides" also carry quality risks. Purity, sterility and labeled dose can vary. That's a real concern for anything injected.

## Is Cartalax Legal and FDA-Approved?

Cartalax is not FDA-approved for any medical use. It is often sold labeled "for research use only," which means not for human use. TelosRX does not currently offer Cartalax.

Any peptide therapy should involve a licensed prescriber and a regulated pharmacy. Treatment decisions are subject to medical approval by a licensed provider.

## Cartalax vs BPC-157 vs GHK-Cu: Evidence Compared

If joint and tissue support is your interest, it helps to compare research depth.

| Peptide | Main research focus | Evidence depth | FDA status |
| --- | --- | --- | --- |
| Cartalax (AED) | Cartilage and aging cell markers | A few cell studies, one research group | Not FDA-approved |
| BPC-157 | Tendon, ligament and gut repair models | Many preclinical studies; limited human data | Not FDA-approved |
| GHK-Cu | Skin, wound and collagen models | Preclinical plus some topical human studies | Not FDA-approved |

Exploring recovery support? TelosRX offers compounded [BPC-157 + TB-500](https://www.telosrx.com/pages/bpc-157-tb500) and [GHK-Cu](https://www.telosrx.com/pages/ghk-cu) protocols. These are not FDA-approved, and access is subject to medical approval by a licensed provider through our asynchronous online review.

## How to Read Bioregulator Research

-   **Check the model.** Cell, animal or human? Each step up matters.
-   **Check the source.** One lab, or several independent teams?
-   **Check the outcome.** A gene marker isn't a symptom or a function.
-   **Check the language.** "Modulates expression" is not "repairs cartilage."

The same lens applies to related bioregulators. See our reviews of [Thymalin research](https://www.telosrx.com/blogs/peptides/thymalin-peptide-research) and [Pinealon vs Epitalon](https://www.telosrx.com/blogs/peptides/pinealon-vs-epitalon-comparison).

## Questions to Ask a Provider

-   What does the human evidence say for my specific goal?
-   Are there options with deeper research behind them?
-   Where would the product come from, and how is quality verified?
-   What labs or follow-up would make sense?

## The Bottom Line on Cartalax Peptide

Cartalax peptide is an interesting research compound with a thin evidence base. Cell studies show shifts in aging-related markers. Human proof of joint or skin benefit doesn't exist yet. Curiosity is fine. Caution is smarter.

## Frequently Asked Questions

### What is Cartalax peptide used for?

Cartalax peptide is promoted online for cartilage and joint support and for skin aging. Those uses are not established. Published research consists of cell-culture studies showing changes in aging-related markers and gene expression. No human clinical trials have been published in indexed journals, and Cartalax is not FDA-approved for any use.

### Is Cartalax safe?

Nobody can say with confidence. There are no published human safety trials, dose-finding studies or long-term data. Short peptides break down into ordinary amino acids, which may suggest low toxicity, but that is not proof. Products labeled for research use also carry purity and sterility risks.

### What is the AED peptide?

AED stands for Ala-Glu-Asp, a chain of three amino acids: alanine, glutamic acid and aspartic acid. It is the active sequence in Cartalax. Researchers identified it as a component of cartilage-derived peptide complexes and studied it in aging cell cultures, including skin fibroblasts and mesenchymal stem cells.

### Does Cartalax repair cartilage?

There is no published evidence that Cartalax repairs cartilage in people or animals. The strongest data come from cell studies, where AED changed markers linked to cell aging and tissue breakdown. Those results are early signals that would need animal and human trials to confirm any real-world effect.

### How does Cartalax compare to BPC-157?

Both are not FDA-approved, but their evidence differs. BPC-157 has many preclinical studies in tendon, ligament and gut repair models, though human data are limited. Cartalax has a handful of cell studies from a single research group. Neither has proven human outcomes, so provider guidance is essential.

### Can I get Cartalax from TelosRX?

TelosRX does not currently offer Cartalax. If you are interested in peptide support for recovery or tissue health, you can complete an asynchronous online intake for other compounded peptide protocols. Any prescription is subject to medical approval by a licensed provider, and approval is not guaranteed.

_TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._

Start your private evaluation at [TelosRX](https://telosrx.com).

**Tags:** AED peptide, bioregulator peptides, cartalax peptide, joint health, peptide research, research review

---

> Source: [Telos RX](https://www.telosrx.com/blogs/peptides/cartalax-peptide-research)
